DNA methylation and mechanism of action of 5-azacytidine

Blood

Volumn 111, Issue 4, 2008, Pages 2485-

  Lavelle, Donald ^a   Saunthararajah, Yogen ^b   Desimone, Joseph ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DNA; DNA METHYLTRANSFERASE 1; GAMMA GLOBIN; HEMOGLOBIN F; HYDROXYUREA; SMALL INTERFERING RNA;

BABOON; DNA METHYLATION; DRUG MECHANISM; ENZYME INHIBITION; ERYTHROID CELL; GENE ACTIVATION; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA STABILITY; RNA TRANSCRIPTION; SICKLE CELL ANEMIA; TRANSCRIPTION INITIATION;

EID: 41349121581     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-10-119867     Document Type: Letter

References (15)

1. Mabaera R, Greene MR, Richardson CA, Conine S, Kozul CD, Lowrey CH. Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. Blood. 2008;111:411-420.
2. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970;30:2760-2769.
3. Vesely J, Cihak A. Incorporation of a potent antileukemia agent, 5-aza-2′-deoxycytiidine, into DNA of cells from leukemic mice. Cancer Res. 1977;37:3684-3689.
4. Momparler RL, Vesely J, Momparler LF, Rivard GE. Synergistic action of 5-aza-2′-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells. Cancer Res. 1979;39:3822-3827.
5. DeSimone J, Heller P, Molokie RE, Hall L, Zwiers D. Tetrahydrouridine, cytidine analogues, and hemoglobin F. Am J Hematol. 1985;18:283-288.
6. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102:3865-3870.
7. DeSimone J, Heller P, Hall L, Zwiers D. 5-azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A. 1982;7:4428-4431.
8. Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+-thalassemia. N Engl J Med. 1982;307:1469-1476.
9. Ley TJ, DeSimone J, Noguchi CT, et al. 5-azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood. 1983;62:370-380.
10. Lowrey CH, Nienhuis AW. Treatment with 5-azacitidine of patients with end-stage β-thalassemia. N Engl J Med. 1993;329:845-848.
11. Koshy M, Dorn L, Bressler L, et al. 2-deoxycytidine-5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96:2379-2384.
12. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002;99:3905-3908.
13. Lavelle D, Vaitkus K, Hankewych M, Singh M, DeSimone J. Effect of 5-aza-2′-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the ε-, γ-, and β-globin gene promoters in Papio anubis. Exp Hematol. 2006;34:339-347.
14. Rhee I, Jair KW, Yen RW, et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature. 2000;404:1003-1007.
15. Ting AH, Jair KW, Schubel KE, Baylin SB. Differential requirement for DNA methyltransferase I in maintaining human cancer cell gene promoter hypermethylation. Cancer Res. 2006;66:729-735.